Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation.
Although clinical trials using anti-CD40L mAb have been halted, blockade of CD40-CD40L interactions has given promising results in rodent and nonhuman primate models. Recently, new insights into the consequences of blocking CD40-CD40L interactions have led to the possibility of overcoming the thromboembolic complications previously associated with this strategy and may pave the way for successful tolerance induction. This mini review will address the issues relating to CD40-CD40L blockade in allotransplantation.
Li
Xian-Liang
XL
INSERM, U643, Nantes, 44093 France.
Ménoret
Séverine
S
Le Mauff
Brigitte
B
Angin
Mathieu
M
Anegon
Ignacio
I
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology*; D019013:CD40 Antigens / Q000037:antagonists & inhibitors* / Q000378:metabolism; D023201:CD40 Ligand / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D016377:Organ Transplantation; D015398:Signal Transduction / Q000187:drug effects* / Q000276:immunology; D013923:Thromboembolism / Q000139:chemically induced; D023001:Transplantation Tolerance / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D019013:CD40 Antigens; D007166:Immunosuppressive Agents; D023201:CD40 Ligand